Payment overview · 2025
General Payments
$588.71
30 reported records · 12 companies
Healthcare provider profile · identity verified
Culber Mack Shotts, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PARAGOULD, AR · NPI 1427011410
Verified facts
What the public records show
CMS Open Payments records show Culber Mack Shotts, M.D. received $588.71 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.78 | 24.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $134.72 | 22.9% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.38 | 10.8% | 3 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $55.97 | 9.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.31 | 7.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.06 | 5.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.18 | 4.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.93 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.16 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.41 | 2.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.12 | 2.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.69 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $588.71 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $143.78 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $91.56 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $80.19 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.27 | 7 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $55.97 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.68 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.06 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.47 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.47 | 2 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 470 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 128 |
| Gabapentin | Gabapentin | 354 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 333 | 110 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 277 | 79 |
| Alprazolam | Alprazolam | 273 | 44 |
| Omeprazole | Omeprazole | 250 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 70 |
| Diclofenac Sodium | Diclofenac Sodium | 227 | 82 |
| Lisinopril | Lisinopril | 225 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 220 | 55 |
| Trazodone Hcl | Trazodone Hcl | 212 | 61 |
| Furosemide | Furosemide | 202 | 69 |
| Metformin Hcl | Metformin Hcl | 202 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 184 | 41 |
| Tramadol Hcl | Tramadol Hcl | 167 | 66 |
| Meloxicam | Meloxicam | 166 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 47 |
| Losartan Potassium | Losartan Potassium | 163 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 162 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 42 |
| Clonazepam | Clonazepam | 130 | 21 |
| Potassium Chloride | Potassium Chloride | 122 | 41 |
| Ondansetron Odt | Ondansetron | 120 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 34 |
| Ozempic | Semaglutide | 114 | 25 |
| Famotidine | Famotidine | 110 | 24 |
| Azithromycin | Azithromycin | 103 | 86 |
| Ibuprofen | Ibuprofen | 102 | 33 |
| Mounjaro | Tirzepatide | 97 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 26 |
| Olanzapine | Olanzapine | 89 | 17 |
| Carvedilol | Carvedilol | 82 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 15 |
| Glipizide | Glipizide | 80 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 20 |
| Pregabalin | Pregabalin | 74 | 21 |
| Promethazine Hcl | Promethazine Hcl | 74 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 22 |
| Finasteride | Finasteride | 72 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 21 |
| Eliquis | Apixaban | 71 | 21 |
| Diazepam | Diazepam | 70 | 13 |
| Meclizine Hcl | Meclizine Hcl | 69 | 24 |
| Sertraline Hcl | Sertraline Hcl | 68 | 17 |
| Simvastatin | Simvastatin | 68 | 22 |
| Allopurinol | Allopurinol | 66 | 16 |
| Donepezil Hcl | Donepezil Hcl | 66 | 20 |
| Lorazepam | Lorazepam | 66 | 13 |
| Atenolol | Atenolol | 65 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 62 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 21 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 57 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 23 |
| Alendronate Sodium | Alendronate Sodium | 54 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 53 | 48 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 52 | suppressed |
| Fluconazole | Fluconazole | 52 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 20 |
| Clonidine Hcl | Clonidine Hcl | 51 | 18 |
| Metformin Hcl Er | Metformin Hcl | 51 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 16 |
| Buspirone Hcl | Buspirone Hcl | 49 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 12 |
| Metoprolol Succinate | Metoprolol Succinate | 45 | 16 |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Nitroglycerin | Nitroglycerin | 44 | 22 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | 11 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Ezetimibe | Ezetimibe | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 39 | suppressed |
| Mupirocin | Mupirocin | 39 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Bupropion Xl | Bupropion Hcl | 37 | 11 |
| Naproxen | Naproxen | 37 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Amoxicillin | Amoxicillin | 36 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Topiramate | Topiramate | 26 | 12 |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 12 |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 15 |
| Loperamide | Loperamide Hcl | 20 | 16 |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 12 |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Prednisone | Prednisone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 12 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $588.71 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dyanavel XR, FARXIGA, INCEPTIV, Kerendia, Ozempic, PAXLOVID, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZENPEP | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error